Determination of Grade and Receptor Status from the Primary Breast Lesion by Magnetic Resonance Spectroscopy

Abstract

Magnetic resonance spectra (MRS) from fine needle aspiration biopsies (FNAB) from primary breast lesions were analysed using a pattern recognition method, Statistical Classification Strategy, to assess tumor grade and oestrogen receptor (ER) and progesterone receptor (PgR) status. Grade 1 and 2 breast cancers were separated from grade 3 cancers with a sensitivity and specificity of 96% and 95%, respectively. The ER status was predicted with a sensitivity of 91% and a specificity of 90%, and the PgR status with a sensitivity of 91% and a specificity of 86%. These classifiers provide rapid and reliable, computerized information and may offer an objective method for determining these prognostic indicators simultaneously with the diagnosis of primary pathology and lymph node involvement.

Keywords

Breast neoplasms Fine needle aspiration spectroscopy (FNAS)Tumor grade Receptor status Magnetic resonance Statistical analysis

References

Mountford

Doran

Lean

, and Russell

Proton MRS can Determine the Pathology of Human Cancers With a High Level of Accuracy. Chem. Rev. 104, 3677–3704 (2004).

Mountford

C. E.

Doran

Lean

C. L.

, and Russell

Cancer Pathology in the Year 2000. Biophys. Chem. 68, 127–135 (1997).

Lean

C. L.

Delbridge

Russell

Diagnosis of Follicular Thyroid Lesions by Proton Magnetic Resonance on Fine Needle Biopsy. J. Clin. Endocrinol. Metab. 80, 1306–1311 (1995).

Russell

Lean

C. L.

Delbridge

May

G. L.

Dowd

, and Mountford

C. E.

Proton Magnetic Resonance and Human Thyroid Neoplasia. I: Discrimination Between Benign and Malignant Neoplasms. Am. J. Med. 96, 383–388 (1994).

Barry

P. A.

Wadstrom

Falk

G. D.

In The Oesophagrogastric Junction. Ed. Giuli

(1998).

Somorjai

Dolenko

Nikulin

Distinguishing Normal Allografts from Biopsy-Proven Rejections: Application of a Three-stage Classification Strategy to Urine MR and IR Spectra. Vib. Spectros. 28, 97–102 (2002).

Lean

C. L.

Somorjai

R. L.

Smith

I. C. P.

Russell

, and Mountford

C. E.

In Annual Reports NMR Spectroscopy, Vol. 48. Ed. Webb

Academic Press (2002).

't Hart

Vogels

Spijksma

Brok

Polman

, and van der Greef

1H-NMR Spectroscopy Combined with Pattern Recognition Analysis Reveals Characteristic Chemical Patterns in Urines of MS Patients and Non-human Primates with MS-like Disease. J. Neurol. Sci. 212, 21–30 (2003).

Rush

Somorjai

Deslauriers

Shaw

Jeffery

, and Nickerson

Subclinical Rejection — A Potential Surrogate Marker for Chronic Rejection — May be Diagnosed by Protocol Biopsy or Urine Spectroscopy. Ann. Transplant. 5, 44–49 (2000).

10.

Mountford

C. E.

Somorjai

R. L.

Malycha

Diagnosis and Prognosis of Breast Cancer by Magnetic Resonance Spectroscopy of Fine-needle Aspirates Analyzed using a Statistical Classification Strategy. Br. J. Surg. 88, 1234–1240 (2001).

11.

Kerlikowske

Grady

Barclay

Sickles

E. A.

, and Ernster

Likelihood Ratios for Modern Screening Mammography. Risk of Breast Cancer Based on Age and Mammographic Interpretation. [Comment]. Jama. 276, 39–43 (1996).

12.

Somorjai

Alexander

Baumgartner

In Artificial Intelligence Methods and Tools for Systems Biology. Ed., Azuaje

F. D. W.

e. Kluwer Academic Publishers, Boston (in press) (2004).

13.

Reo

N. V.

NMR-Based Metabonomics. Drug & Chemical Toxicology 25, 375–382 (2002).

14.

Hagberg

From Magnetic Resonance Spectroscopy to Classification of Tumors. A Review of Pattern Recognition Methods. NMR Biomed. 11, 148–156 (1998).

15.

El-Deredy

W. A.

Pattern Recognition Approaches in Biomedical and Clinical Magnetic Resonance Spectroscopy. NMR Biomed. 10, 99–124 (1997).

16.

Australian Cancer Network Working Party. The Pathology Reporting of Breast Cancer, A Guide for Pathologists, Surgeons Radiologists and Oncologists. 2nd edition, October 2001.

17.

Nikulin

Dolenko

Bezabeh

, and Somorjai

Near-optimal Region Selection for Feature Space Reduction: Novel Preprocessing Methods for Classifying MR Spectra. NMR Biomed. 11, 209–217 (1998).

18.

Mountford

C. E.

and Mackinnon

W. B.

Proton Magnetic Resonance Spectroscopy of Lymphocytes: An Historical Perspective. Immunomethods 4, 98–112 (1994).

19.

Wright

L. C.

May

G. L.

Gregory

Inhibition of Metastatic Potential by Fucosidase: An NMR Study Identifies a Cell Surface Metastasis Marker. J. Cell Biochem. 37, 49–59 (1988).

20.

Lean

C. L.

Mackinnon

W. B.

Delikatny

E. J.

Whitehead

R. H.

, and Mountford

C. E.

Cell-surface Fucosylation and Magnetic Resonance Spectroscopy Characterization of Human Malignant Colorectal Cells. Biochemistry 31, 11095–11105 (1992).

21.

Mackinnon

W. B.

Huschtscha

Dent

Hancock

Paraskeva

, and Mountford

C. E.

Correlation of Cellular Differentiation in Human Colorectal Carcinoma and Adenoma Cell Lines with Metabolite Profiles Determined by 1H Magnetic Resonance Spectroscopy. Int. J. Cancer 59, 248–261 (1994).

22.

Weidner

Prognostic Factors in Breast Carcinoma. Curr. Opin. Obstet. Gynecol. 7, 4–9 (1995).

23.

Fisher

Ravdin

R. G.

Ausman

R. K.

Slack

N. H.

Moore

G. E.

, and Noer

R. J.

Surgical Adjuvant Chemotherapy in Cancer of the Breast: Results of a Decade of Cooperative Investigation. Ann. Surg. 168, 337–356 (1968).

24.

Silverstein

M. J.

Gierson

E. D.

Waisman

J. R.

Senofsky

G. M.

Colburn

W. J.

, and Gamagami

Axillary Lymph Node Dissection for T1a Breast Carcinoma. Is it Indicated?

Cancer 73, 664–667 (1994).

25.

Chen

Y. Y.

and Schnitt

S. J.

Prognostic Factors for Patients with Breast Cancers 1cm and Smaller. Breast Cancer Res. Treat. 51, 209–225 (1998).

26.

Jensen

E. V.

and Jordon

V. C.

The Estrogen Receptor: A Model for Molecular Medicine. Clin. Cancer Res. 9, 1980–1989 (2003).

27.

Bardou

V. J.

Arpino

Elledge

R. M.

Osborne

C. K.

, and Clark

G. M.

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases. J. Clin. Oncol. 21, 1973–1979 (2003).